Moleculin Biotech reports interim MIRACLE trial data showing higher remission rates in relapsed/refractory AML
MBRX•Trial timeline and safety update
Enrollment is expected to reach 90 patients in September 2026, setting up an unblinded efficacy readout in December 2026 to February 2027.
Part B is expected to start in the first half of 2027 once the company selects an optimal dose from Part A results.
The company reported no cardiotoxicity signals to date, supporting a safety profile that could aid positioning if efficacy holds.
Interim MIRACLE data show higher remission rates
Moleculin Biotech highlighted interim results already presented from its pivotal MIRACLE study of Annamycin in relapsed or refractory AML.
The update showed patients receiving Annamycin were more likely to reach remission than those on the control regimen.
